Your browser doesn't support javascript.
loading
CD56bright NK cells exhibit potent antitumor responses following IL-15 priming.
Wagner, Julia A; Rosario, Maximillian; Romee, Rizwan; Berrien-Elliott, Melissa M; Schneider, Stephanie E; Leong, Jeffrey W; Sullivan, Ryan P; Jewell, Brea A; Becker-Hapak, Michelle; Schappe, Timothy; Abdel-Latif, Sara; Ireland, Aaron R; Jaishankar, Devika; King, Justin A; Vij, Ravi; Clement, Dennis; Goodridge, Jodie; Malmberg, Karl-Johan; Wong, Hing C; Fehniger, Todd A.
Afiliación
  • Wagner JA; Department of Medicine, Division of Oncology, Washington University School of Medicine, St. Louis, Missouri, USA.
  • Rosario M; Department of Medicine, Division of Oncology, Washington University School of Medicine, St. Louis, Missouri, USA.
  • Romee R; Department of Medicine, Division of Oncology, Washington University School of Medicine, St. Louis, Missouri, USA.
  • Berrien-Elliott MM; Department of Medicine, Division of Oncology, Washington University School of Medicine, St. Louis, Missouri, USA.
  • Schneider SE; Department of Medicine, Division of Oncology, Washington University School of Medicine, St. Louis, Missouri, USA.
  • Leong JW; Department of Medicine, Division of Oncology, Washington University School of Medicine, St. Louis, Missouri, USA.
  • Sullivan RP; Department of Medicine, Division of Oncology, Washington University School of Medicine, St. Louis, Missouri, USA.
  • Jewell BA; Department of Medicine, Division of Oncology, Washington University School of Medicine, St. Louis, Missouri, USA.
  • Becker-Hapak M; Department of Medicine, Division of Oncology, Washington University School of Medicine, St. Louis, Missouri, USA.
  • Schappe T; Department of Medicine, Division of Oncology, Washington University School of Medicine, St. Louis, Missouri, USA.
  • Abdel-Latif S; Department of Medicine, Division of Oncology, Washington University School of Medicine, St. Louis, Missouri, USA.
  • Ireland AR; Department of Medicine, Division of Oncology, Washington University School of Medicine, St. Louis, Missouri, USA.
  • Jaishankar D; Department of Medicine, Division of Oncology, Washington University School of Medicine, St. Louis, Missouri, USA.
  • King JA; Department of Medicine, Division of Oncology, Washington University School of Medicine, St. Louis, Missouri, USA.
  • Vij R; Department of Medicine, Division of Oncology, Washington University School of Medicine, St. Louis, Missouri, USA.
  • Clement D; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Radiumhospitalet, Oslo, Norway.
  • Goodridge J; The KG Jebsen Centre for Cancer Immunotherapy, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
  • Malmberg KJ; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Radiumhospitalet, Oslo, Norway.
  • Wong HC; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Radiumhospitalet, Oslo, Norway.
  • Fehniger TA; The KG Jebsen Centre for Cancer Immunotherapy, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
J Clin Invest ; 127(11): 4042-4058, 2017 Nov 01.
Article en En | MEDLINE | ID: mdl-28972539
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Células Asesinas Naturales / Leucemia Mieloide Aguda / Interleucina-15 / Mieloma Múltiple Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Revista: J Clin Invest Año: 2017 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Células Asesinas Naturales / Leucemia Mieloide Aguda / Interleucina-15 / Mieloma Múltiple Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Revista: J Clin Invest Año: 2017 Tipo del documento: Article País de afiliación: Estados Unidos